X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (149250) 149250
Newspaper Article (31073) 31073
Newsletter (22251) 22251
Web Resource (773) 773
Magazine Article (771) 771
Trade Publication Article (489) 489
Transcript (469) 469
Book Chapter (284) 284
Dissertation (267) 267
Conference Proceeding (144) 144
Book / eBook (133) 133
Publication (105) 105
Book Review (42) 42
Reference (15) 15
Streaming Video (13) 13
Government Document (3) 3
Journal / eJournal (2) 2
Paper (2) 2
Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (88117) 88117
lung cancer (83342) 83342
oncology (67452) 67452
cancer (59354) 59354
lung cancer, non-small cell (55967) 55967
female (46330) 46330
male (44807) 44807
research (42179) 42179
middle aged (37838) 37838
aged (35556) 35556
chemotherapy (33661) 33661
lung neoplasms - pathology (32237) 32237
care and treatment (30408) 30408
metastasis (27230) 27230
tumors (25610) 25610
adult (23468) 23468
prognosis (23082) 23082
carcinoma, non-small-cell lung - pathology (22297) 22297
lung neoplasms - drug therapy (21903) 21903
cancer therapies (21875) 21875
oncology, experimental (21526) 21526
carcinoma, non-small-cell lung - drug therapy (18701) 18701
non-small cell lung cancer (17455) 17455
lung neoplasms - genetics (16746) 16746
analysis (16177) 16177
mutation (16129) 16129
respiratory system (15915) 15915
lung cancer, small cell (15649) 15649
apoptosis (15483) 15483
genetic aspects (15372) 15372
aged, 80 and over (15003) 15003
expression (14694) 14694
patients (14421) 14421
survival (14411) 14411
neoplasm staging (14367) 14367
animals (13998) 13998
surgery (13591) 13591
clinical trials (13389) 13389
cell lung-cancer (13328) 13328
lung-cancer (13264) 13264
cell line, tumor (13256) 13256
health aspects (13078) 13078
medical research (12304) 12304
carcinoma, non-small-cell lung - genetics (12075) 12075
proteins (11780) 11780
carcinoma (11692) 11692
gene expression (11664) 11664
lung neoplasms - metabolism (11563) 11563
lung neoplasms - mortality (11505) 11505
treatment outcome (11451) 11451
radiotherapy (11274) 11274
medical prognosis (10979) 10979
immunotherapy (10198) 10198
kinases (9936) 9936
adenocarcinoma (9891) 9891
studies (9660) 9660
development and progression (9570) 9570
retrospective studies (9461) 9461
carcinoma, non-small-cell lung - mortality (9403) 9403
pharmaceutical industry (9347) 9347
lung neoplasms - surgery (9202) 9202
diagnosis (9138) 9138
physical fitness (8905) 8905
mice (8837) 8837
antineoplastic combined chemotherapy protocols - therapeutic use (8446) 8446
cell biology (8261) 8261
breast cancer (8156) 8156
epidermal growth factor (8083) 8083
immunohistochemistry (8082) 8082
carcinoma, non-small-cell lung - metabolism (8002) 8002
medicine (7983) 7983
drug therapy (7862) 7862
survival analysis (7756) 7756
antineoplastic agents - therapeutic use (7738) 7738
non-small cell lung carcinoma (7672) 7672
biomarkers (7642) 7642
medicine & public health (7624) 7624
breast-cancer (7384) 7384
risk factors (7342) 7342
hematology, oncology and palliative medicine (7315) 7315
survival rate (7295) 7295
gefitinib (7263) 7263
therapy (7142) 7142
carcinoma, non-small-cell lung - surgery (7103) 7103
radiology, nuclear medicine & medical imaging (6536) 6536
pathology (6530) 6530
lung neoplasms - therapy (6471) 6471
cisplatin (6425) 6425
radiation therapy (6409) 6409
gene expression regulation, neoplastic (6370) 6370
lung neoplasms - diagnosis (6316) 6316
pharmacology & pharmacy (6259) 6259
research article (6146) 6146
nsclc (6114) 6114
biochemistry & molecular biology (6055) 6055
antineoplastic agents (6027) 6027
genes (5914) 5914
lung neoplasms - radiotherapy (5875) 5875
metastases (5823) 5823
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (33) 33
Online Resources - Online (27) 27
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (14) 14
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Scarborough Hospital - Online (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Lakeridge Health Sciences - Online (1) 1
Media Commons - Microtexts (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (199151) 199151
Chinese (2983) 2983
Japanese (1755) 1755
French (1688) 1688
German (886) 886
Spanish (369) 369
Korean (306) 306
Polish (273) 273
Russian (245) 245
Portuguese (153) 153
Turkish (133) 133
Italian (111) 111
Czech (64) 64
Hungarian (49) 49
Dutch (26) 26
Serbian (18) 18
Bulgarian (17) 17
Danish (16) 16
Romanian (15) 15
Croatian (11) 11
Slovak (10) 10
Icelandic (9) 9
Finnish (8) 8
Norwegian (8) 8
Lithuanian (7) 7
Swedish (6) 6
Urdu (6) 6
Hebrew (5) 5
Slovenian (4) 4
Ukrainian (3) 3
Persian (2) 2
Arabic (1) 1
Belarusian (1) 1
Bosnian (1) 1
Greek (1) 1
Hindi (1) 1
Latvian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 13, pp. 1189 - 1197
...–small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases. 2 – 8 ALK -rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation (T790M... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 9, pp. 829 - 838
...–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse. 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Clinical cancer research, ISSN 1557-3265, 2018, Volume 24, Issue 14, pp. 3334 - 3347
Purpose: Despite initial benefit from tyrosine kinase inhibitors (TKIs), patients with advanced non-small cell lung cancer (NSCLC) harboring ALK (ALK(+)) and ROS1 (ROS1... 
MUTATION CONFERS RESISTANCE | ONCOLOGY | OVERCOMES CRIZOTINIB RESISTANCE | EML4-ALK FUSION | COPY NUMBER | IN-SITU HYBRIDIZATION | GENE REARRANGEMENT | LYMPHOMA KINASE ALK | TUMOR-CELLS | INHIBITOR | NSCLC PATIENTS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Molecular Targeted Therapy | Biomarkers, Tumor | Anaplastic Lymphoma Kinase - genetics | DNA Copy Number Variations | Young Adult | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - chemistry | Protein-Tyrosine Kinases - chemistry | Adult | Female | Anaplastic Lymphoma Kinase - chemistry | Lung Neoplasms - genetics | Computational Biology - methods | Carcinoma, Non-Small-Cell Lung - genetics | Models, Molecular | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Drug Resistance, Neoplasm - genetics | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | High-Throughput Nucleotide Sequencing | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung Neoplasms - diagnosis | Tyrosine | Neuregulin 1 | Epidermal growth factor receptors | Genes | Lung cancer | Non-small cell lung carcinoma | Drug resistance | Kinases | Patients | ErbB-2 protein | Gene fusion | Genetic screening | Gene sequencing | Polymerase chain reaction | β-catenin | Ret protein | Experimental design | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | DNA sequencing | Cancer | Proto-oncogenes | non-small cell lung cancer | ALK | tyrosine kinase inhibitor | ROS1 | acquired resistance
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 18, pp. 1689 - 1699